Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

The only thing that can come of this will make vaccines less insurable and less available," a vaccine expert at Children’s ...

The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.